FARALLON CAPITAL MANAGEMENT LLC
Position in RNA — Atrium Therapeutics, Inc.
CIK 909661
SAN FRANCISCO, CA
Position in RNA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,670,943
New position
Shares Held
349,360
first reported quarter
Ownership
2.04%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026FARALLON CAPITAL MANAGEMENT LLC holds $5,160,870,541 across 65 Biotechnology names. RNA ranks #22 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
13,604,796 | $1,323,066,411 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
9,365,463 | $695,479,282 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
6,348,906 | $669,174,692 | |
| 4 | EXEL |
Exelixis, Inc.
|
13,111,010 | $562,331,218 | |
| 5 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
8,338,098 | $302,839,719 | |
| 6 | ROIV |
Roivant Sciences Ltd.
|
9,675,000 | $267,997,500 | |
| 7 | BEAM |
Beam Therapeutics Inc.
|
10,134,696 | $241,509,805 | |
| 8 | AGIO |
Agios Pharmaceuticals, Inc.
|
5,684,000 | $192,289,720 |
All Filings in RNA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,670,943 | 349,360 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||